SD Biosensor에스디바이오센서

SD Biosensor's revenue is roughly flat, but it is still loss-making at the operating and net level, and the share price is well below its 52-week high.

SD Biosensor sells in vitro diagnostic tests and instruments for infectious and chronic diseases, sold through hospitals, clinical labs and public programmes. On trailing twelve-month figures to H1 2026 it had revenue of ₩739B, an operating loss of ₩65B and a net loss of ₩729B, with ₩230B in cash and no borrowings reported. The shares closed at ₩6,630 on 2026-10-15, down 31.3% over one year and about 35% below the 52-week high of ₩10,190.

What stands out

• Revenue has stayed around ₩655B to ₩739B since 2023, after the sharp drop from the ₩2.9T of 2021 and 2022.
• Annual operating losses widened to ₩81B in 2025 from ₩54B in 2024, and the trailing net loss of ₩729B is far larger than the operating loss, which the data does not explain.
• Price-to-book is 0.3 and the data shows a 3% dividend yield, but there is no meaningful P/E because earnings are negative.
• Trailing free cash flow was slightly negative at about -₩0.3B, and liabilities are 20.6% of equity.
• Recent filings are mostly routine (half-year report, insider and 5%+ holding reports, IR events), plus a loan extension decision in July 2026; no news headlines were included in the data.

What to watch

• The next quarterly or annual results, to see whether losses narrow from the trailing levels.
• Explanation of the large gap between the operating loss and the net loss in the half-year report, which the data does not cover.
• Any further filings on the loan extension and the lawsuit noted in March 2026, whose outcome is not in the data.